Literature DB >> 11228488

A comparison of costs associated with screening for gestational diabetes with two-tiered and one-tiered testing protocols.

J P Lavin1, B Lavin, N O'Donnell.   

Abstract

OBJECTIVE: The Fourth International Workshop on Gestational Diabetes recently suggested that two techniques, a 2-tiered protocol and a 1-tiered protocol, to screen for gestational diabetes mellitus are acceptable alternatives. This study was undertaken to compare the direct costs and patient time expenditures associated with implementing both techniques. STUDY
DESIGN: A MEDLINE search was undertaken to determine the prevalence of positive and negative screening results. Direct costs of testing were estimated by determining the range of supply costs from manufacturers' catalogs and the labor costs by estimating the time required to perform each procedure and multiplying by the appropriate range of wages; these costs were then multiplied by the appropriate range of the number of procedures required to implement both protocols, and the totals were summed. Patient time expended was estimated by assigning test times of 1, 2, and 3 hours for the 50-g screening glucose challenge test, the 75-g oral glucose tolerance test, and the 100-g oral glucose tolerance test, respectively. If additional visits were required, 2 travel-time units were assigned each time a patient underwent a procedure. These units were multiplied by the range of patients undergoing various tests to implement the alternative protocols.
RESULTS: We identified low and high direct costs, test times, and travel units per patient screened by the 1- and 2-tiered testing protocols. Low and high direct costs were $3.46 and $7.88, respectively, for the 2-tiered protocol and $5.64 and $10.88, respectively, for the 1-tiered protocol (relative ratios, 1.63 for low direct costs in each protocol and 1.38 for high direct costs in each protocol). Low and high test times were 1.4 and 1.5 hours, respectively, for the 2-tiered protocol and 2.0 and 2.0 hours, respectively, for the 1-tiered protocol (relative ratios, 1.47 for low test times in each protocol and 1.32 for high test times in each protocol). Low and high travel units for the 2-tiered protocol were 0.2 and 0.3, respectively, when the glucose challenge test was given at the prenatal visit, and 2.2 and 2.3, respectively, when the test was not given at that time. Low and high travel units for the 1-tiered protocol were 8.3 and 5.8, respectively, when the glucose challenge test was given at the prenatal visit, and 0.89 and 0.85, respectively, when the test was not given at that time.
CONCLUSIONS: The 2-tiered protocol appears to be associated with lower direct implementation costs and less patient time expenditure than the 1-tiered scheme. The 1-tiered protocol is associated with slightly less travel time, but this is unlikely to offset the test time advantage of the 2-tiered protocol. Until further data regarding the relative clinical utility of the 2 protocols become available, these factors may be important for clinicians in deciding which screening format to follow.

Entities:  

Mesh:

Year:  2001        PMID: 11228488     DOI: 10.1067/mob.2001.109401

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  3 in total

1.  New recommendations for the diagnosis of diabetes in pregnancy.

Authors:  Carol J Homko
Journal:  Curr Diab Rep       Date:  2011-02       Impact factor: 4.810

2.  Predictive Characteristics of Elevated 1-Hour Glucose Challenge Test Results for Gestational Diabetes.

Authors:  Alan T N Tita; Yinglei Lai; Mark B Landon; Susan M Ramin; Brian Casey; Ronald J Wapner; Michael W Varner; John M Thorp; Anthony Sciscione; Patrick Catalano; Margaret Harper; George R Saade; Steve N Caritis; Yoram Sorokin; Alan M Peaceman; Jorge E Tolosa
Journal:  Am J Perinatol       Date:  2017-07-19       Impact factor: 1.862

3.  Gestational diabetes mellitus screening using the one-step versus two-step method in a high-risk practice.

Authors:  Kisti P Fuller; Adam F Borgida
Journal:  Clin Diabetes       Date:  2014-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.